Dr. Green on Treatment Regimens for Patients With Multiple Myeloma in Early Relapse

Michael Green, MD
Published: Monday, Nov 12, 2018



Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

As multiple myeloma is a heterogenous disease, there is no standard regimen for patients in early relapse. If a patient does experience early relapse, Green individualizes the regimen to the patient based on the patient’s disease characteristics. Additionally, a physician must consider whether a patient has renal insufficiency or compromise to their kidneys, Green says. Choosing a treatment regimen also depends on whether a patient has liver disease or is experiencing neuropathy, as well as their functional abilities.

Sequencing is another factor to be mindful of, explains Green. Since there are many options for patients, it is important to keep in mind what a patient may need down the line. A physician has to be cognizant of what they use now because it will impact what is available for the patient in the future, concludes Green.
SELECTED
LANGUAGE


Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

As multiple myeloma is a heterogenous disease, there is no standard regimen for patients in early relapse. If a patient does experience early relapse, Green individualizes the regimen to the patient based on the patient’s disease characteristics. Additionally, a physician must consider whether a patient has renal insufficiency or compromise to their kidneys, Green says. Choosing a treatment regimen also depends on whether a patient has liver disease or is experiencing neuropathy, as well as their functional abilities.

Sequencing is another factor to be mindful of, explains Green. Since there are many options for patients, it is important to keep in mind what a patient may need down the line. A physician has to be cognizant of what they use now because it will impact what is available for the patient in the future, concludes Green.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x